Targeting the Phosphatidylinosital 3-Kinase, Akt, and Mammalian Target of Rapamycin Pathway in Non-small Cell Lung Cancer

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages S1805-S1807

  Cuffe, Sinead ^a   Leighl, Natasha B ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES;

MLCS; MLOWN;

EID: 84857074185     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000407566.37523.c5     Document Type: Article

References (13)

1. Tsurutani, J, Fukuoka, J, Tsurutani, H, et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 24 (2006), 306–314.
2. Tang, JM, He, QY, Guo, RX, et al. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51 (2006), 181–191.
3. Balsara, BR, Pei, J, Mitsuuchi, Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25 (2004), 2053–2059.
4. West, KA, Linnoila, IR, Brognard, J, et al. Tobacco carcinogen-induced cellular transformation increases Akt activation in vitro and in vivo. Chest 125:Suppl 5 (2004), 101S–102S.
5. West, KA, Linnoila, IR, Belinsky, SA, et al. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3′-kinase/Akt pathway in vitro and in vivo. Cancer Res 64 (2004), 446–451.
6. Blumenthal, GM, Ballas, MS, Bernstein, W, et al. A phase I/II trial of pemetrexed and sirolimus in advanced NSCLC. J Clin Oncol (Meeting Abstracts), 28(Suppl 15), 2010, 7600.
7. Papadimitrakopoulou, V, Soria, JC, Douillard, JY, et al. A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I). J Clin Oncol (Meeting Abstracts), 25(Suppl 18), 2007, 7589.
8. Price, KA, Azzoli, CG, Krug, LM, et al. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol 5 (2010), 1623–1629.
9. Oza, AM, Kollmannsberger, C, NCIC Clinical Trials Group, et al. Phase I study of temsirolimus (CCL-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179. J Clin Oncol (Meeting Abstracts), 27(Suppl 15), 2009, 3558.
10. Jimeno, A, Hong, DS, Hecker, S, et al. Final results from a phase I, dose escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. J Clin Oncol (Meeting Abstracts), 28(Suppl 15), 2010, 3089.
11. Baselga, J, De Jonge, MJ, Rodon, J, et al. A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol (Meeting Abstracts), 28(Suppl 15), 2010, 3003.
12. Burris, H, Rodon, J, Sharma, S, et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol (Meeting Abstracts), 28(Suppl 15), 2010, 3005.
13. Tolcher, AW, Yap, TA, Fearen, I, et al. A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumors (ST). J Clin Oncol (Meeting Abstracts), 27(Suppl 15), 2009, 3503.